Ann: OncoSil FY21 half yearly review, page-17

Hi Hyper

Single digit sales by mid year and that really being optimistic. Cannot see any take up with a ravaged hospital system in Europe. No TGA approval until at least June and that’s being optimistic. Can see that dragging well into the second half of the year. No FDA approval until second half of the year. I’m not certain about that one either.

In fact I can only see single digit sales for the full year. No real take up until they sort out all of the required approvals which will take considerable time. For me it’s the reimbursement approvals before we see some real traction. Cannot see any real take up with a device that will have to be paid privately.

So, share price will continue to drift with no real solid announcement until FDA approval (see comment above) and TGA approval to drag on. No real sales until all of the catalysts including reimbursement is achieved. So, look at least until 2022 at the very earliest. More likely much much longer.